Why the study?
What are the dosing, monitoring, and safety outcomes of prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment?
Population
95 critically ill patients ≥ 18 years old who received fondaparinux for ≥ 72 hours with ≥ 1 dose in an…
Design
Cohort
Authors
Loading...
May support anti-Xa monitoring in renally impaired ICU patients; leaves open optimal dosing pending randomized trials.
What are the dosing, monitoring, and safety outcomes of prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment?
In critically ill patients with renal dysfunction, prophylactic fondaparinux leads to drug accumulation and a 4.2% rate of clinically significant bleeding, suggesting empirical dose adjustments and anti-Xa monitoring may be prudent.
Cope et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: